CO6630197A2 - Nuevos procesos - Google Patents
Nuevos procesosInfo
- Publication number
- CO6630197A2 CO6630197A2 CO12208170A CO12208170A CO6630197A2 CO 6630197 A2 CO6630197 A2 CO 6630197A2 CO 12208170 A CO12208170 A CO 12208170A CO 12208170 A CO12208170 A CO 12208170A CO 6630197 A2 CO6630197 A2 CO 6630197A2
- Authority
- CO
- Colombia
- Prior art keywords
- atherosclerosis
- new process
- vascular
- primary
- useful
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 4
- 230000002792 vascular Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000009862 primary prevention Effects 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 230000009863 secondary prevention Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
- C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34522410P | 2010-05-17 | 2010-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6630197A2 true CO6630197A2 (es) | 2013-03-01 |
Family
ID=44992024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12208170A CO6630197A2 (es) | 2010-05-17 | 2012-11-16 | Nuevos procesos |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9447052B2 (enExample) |
| EP (1) | EP2571857B1 (enExample) |
| JP (1) | JP6027529B2 (enExample) |
| KR (1) | KR20130089157A (enExample) |
| CN (2) | CN105837520A (enExample) |
| AR (1) | AR081399A1 (enExample) |
| AU (1) | AU2011256270B2 (enExample) |
| BR (1) | BR112012030532A2 (enExample) |
| CA (1) | CA2799520C (enExample) |
| CL (1) | CL2012003206A1 (enExample) |
| CO (1) | CO6630197A2 (enExample) |
| CR (1) | CR20120630A (enExample) |
| DO (1) | DOP2012000289A (enExample) |
| EA (1) | EA026569B1 (enExample) |
| IL (1) | IL223068A0 (enExample) |
| MA (1) | MA34301B1 (enExample) |
| MX (1) | MX2012013387A (enExample) |
| NZ (1) | NZ603672A (enExample) |
| PE (1) | PE20130318A1 (enExample) |
| PH (1) | PH12012502247A1 (enExample) |
| SG (1) | SG185559A1 (enExample) |
| TW (1) | TW201209043A (enExample) |
| UY (1) | UY33388A (enExample) |
| WO (1) | WO2011146494A1 (enExample) |
| ZA (1) | ZA201208631B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201209043A (en) * | 2010-05-17 | 2012-03-01 | Glaxo Group Ltd | Novel processes |
| WO2015087239A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Processes for the preparation of darapladib and its intermediates |
| WO2015092687A2 (en) | 2013-12-17 | 2015-06-25 | Ranbaxy Laboratories Limited | Process for the purification of darapladib |
| ES2907130T3 (es) | 2017-09-26 | 2022-04-22 | Inst Nat Sante Rech Med | Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes |
| US10866963B2 (en) * | 2017-12-28 | 2020-12-15 | Dropbox, Inc. | File system authentication |
| CN118221687B (zh) | 2023-07-17 | 2024-12-31 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1143516B (de) * | 1961-04-27 | 1963-02-14 | Bayer Ag | Verfahren zur Herstellung von Peptiden |
| US4277465A (en) | 1978-08-26 | 1981-07-07 | Kyoto Yakuhin Kogyo Kabushiki Kaisha | Adjuvant for promoting absorption of therapeutically active substances through the digestive tract |
| US4235776A (en) * | 1979-03-15 | 1980-11-25 | Eli Lilly And Company | Tetrahydro-2H-benzo[c]pyrroles |
| DE2941597A1 (de) * | 1979-10-13 | 1981-04-23 | Basf Ag, 6700 Ludwigshafen | Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
| US4619941A (en) * | 1984-11-19 | 1986-10-28 | American Cyanamid Company | N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents |
| WO1999024420A1 (en) | 1997-11-06 | 1999-05-20 | Smithkline Beecham Plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
| US6750228B1 (en) * | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| WO2000028328A1 (en) | 1998-11-05 | 2000-05-18 | Biocryst Pharmaceuticals, Inc. | New cyclopentane and cyclopentene compounds and use for detecting influenza virus |
| DE60042286D1 (de) * | 1999-05-01 | 2009-07-09 | Smithkline Beecham Plc | Pyrimidinon Verbindungen |
| DE60139429D1 (de) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
| GB0119795D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| TW201209043A (en) * | 2010-05-17 | 2012-03-01 | Glaxo Group Ltd | Novel processes |
-
2011
- 2011-05-16 TW TW100117029A patent/TW201209043A/zh unknown
- 2011-05-16 UY UY33388A patent/UY33388A/es not_active Application Discontinuation
- 2011-05-16 AR ARP110101679 patent/AR081399A1/es unknown
- 2011-05-17 WO PCT/US2011/036821 patent/WO2011146494A1/en not_active Ceased
- 2011-05-17 MA MA35441A patent/MA34301B1/fr unknown
- 2011-05-17 SG SG2012083648A patent/SG185559A1/en unknown
- 2011-05-17 EP EP11784095.9A patent/EP2571857B1/en active Active
- 2011-05-17 BR BR112012030532A patent/BR112012030532A2/pt not_active IP Right Cessation
- 2011-05-17 EA EA201291235A patent/EA026569B1/ru not_active IP Right Cessation
- 2011-05-17 US US13/698,102 patent/US9447052B2/en not_active Expired - Fee Related
- 2011-05-17 MX MX2012013387A patent/MX2012013387A/es unknown
- 2011-05-17 AU AU2011256270A patent/AU2011256270B2/en not_active Ceased
- 2011-05-17 PE PE2012002160A patent/PE20130318A1/es not_active Application Discontinuation
- 2011-05-17 CN CN201610182606.0A patent/CN105837520A/zh active Pending
- 2011-05-17 CA CA2799520A patent/CA2799520C/en not_active Expired - Fee Related
- 2011-05-17 KR KR20127032795A patent/KR20130089157A/ko not_active Abandoned
- 2011-05-17 JP JP2013511295A patent/JP6027529B2/ja not_active Expired - Fee Related
- 2011-05-17 PH PH1/2012/502247A patent/PH12012502247A1/en unknown
- 2011-05-17 CN CN201180035126.7A patent/CN103003249B/zh not_active Expired - Fee Related
- 2011-05-17 NZ NZ60367211A patent/NZ603672A/en not_active IP Right Cessation
-
2012
- 2012-11-15 DO DO2012000289A patent/DOP2012000289A/es unknown
- 2012-11-15 IL IL223068A patent/IL223068A0/en unknown
- 2012-11-16 CO CO12208170A patent/CO6630197A2/es unknown
- 2012-11-16 CL CL2012003206A patent/CL2012003206A1/es unknown
- 2012-11-16 ZA ZA2012/08631A patent/ZA201208631B/en unknown
- 2012-12-12 CR CR20120630A patent/CR20120630A/es unknown
-
2016
- 2016-08-12 US US15/235,468 patent/US9725420B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394473B (es) | Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2. | |
| PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| CO7141404A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
| CO7141403A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles | |
| UY33735A (es) | Compuestos antivirales | |
| IN2014KN02601A (enExample) | ||
| EA201591889A1 (ru) | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd | |
| UY34467A (es) | Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
| IN2015DN00372A (enExample) | ||
| CO2017004530A2 (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| CR20140554A (es) | Compuestos de acido dimetil-benzoico | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| UA108878C2 (ru) | Ингибиторы протеинтирозинкиназной активности | |
| BR112014013138A2 (pt) | anilinas substituídas como antagonistas de ccr(4) | |
| CR20140553A (es) | Compuestos de fenoxietil piperidina | |
| CU24365B1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| UY34719A (es) | Proceso para la producción de inhibidores de crr | |
| CO7141402A2 (es) | Procesos para producir ciertos 2 (piridin 3 il)tiazoles |